The majority of injectable fillers on the market — including the entire JUVÉDERM® and Restylane® lines — are made from hyaluronic acid (HA), a glycosaminoglycan polysaccharide that occurs naturally throughout human connective tissue. Hyaluronic acid on Wikipedia.
In its native form, HA is short-lived — broken down within days by the body’s own hyaluronidase enzyme. The innovation behind injectable HA fillers is cross-linking: a chemical process using BDDE (or similar agents) that bonds HA chains into a durable, viscoelastic 3D gel. This cross-linked gel resists degradation, binds water to maintain volume, and integrates with surrounding tissue. The resulting product’s G-prime (elastic modulus) determines its behavior in the body: high-G-prime gels like Voluma lift and hold structural position; low-G-prime gels like Volbella flow into fine planes without creating stiffness.
The JUVÉDERM® line uses Allergan’s proprietary VYCROSS cross-linking technology. Restylane products use NASHA (Non-Animal Stabilized Hyaluronic Acid) and XpresHAn Technology depending on the specific product. These engineering differences produce gels with distinct performance characteristics in different treatment areas — which is why an injector with access to multiple brands and multiple SKUs consistently produces better outcomes than one limited to a single product.
The first HA filler approved by the FDA was Restylane, which received Premarket Approval (PMA P020023) on December 12, 2003. JUVÉDERM’s family PMA (P050047) followed in 2006. Every FDA-approved filler in Capital Skin’s portfolio has undergone the full Class III medical device Premarket Approval process — the most stringent FDA pathway requiring substantial clinical evidence of safety and effectiveness. FDA Center for Devices and Radiological Health.
The reversibility safety net: One of the most important — and underappreciated — facts about HA fillers is that they can be dissolved. Hyaluronidase, an enzyme that depolymerizes HA chains, can rapidly break down JUVÉDERM or Restylane filler if a result is unsatisfactory or, in emergency cases, if vascular compromise is suspected. Capital Skin’s physician-ownership model means hyaluronidase is on-site and immediately accessible — a critical safety advantage that facilities without on-site MD oversight cannot reliably offer. Hyaluronidase on Wikipedia.
Radiesse — When You Want More Than Just Volume
Radiesse® (manufactured by Merz Aesthetics) operates on a different principle. Its active agent is calcium hydroxylapatite (CaHA) — the same mineral compound that gives bone its rigidity — formulated as tiny microspheres suspended in a carboxymethylcellulose carrier gel. Calcium hydroxylapatite on Wikipedia. FDA-approved since December 2006 (PMA P050052), Radiesse provides immediate volume correction through the carrier gel while its CaHA microspheres create a scaffold that fibroblasts populate with new type I collagen over the following months.
The practical implication: Radiesse doesn’t just fill — it rebuilds. Patients often see progressive improvement in skin quality and thickness well beyond the initial correction, with results lasting 12–18 months or more. It’s particularly well-suited for nasolabial folds, jawline and lower face structural support, and — per its 2015 FDA supplement — dorsal hand rejuvenation. One important clinical distinction: Radiesse is NOT reversible with hyaluronidase. This makes patient selection and pre-treatment counseling essential — Dr. Purcell addresses this in every Radiesse consultation.
Belotero Balance — Precision in Fine Tissue
Belotero Balance® (Merz Aesthetics, FDA PMA P090016, approved November 2011) uses Cohesive Polydensified Matrix (CPM) technology — engineered for mid-dermal injection into fine-to-moderate wrinkles. Its unique integration into skin tissue without the Tyndall effect (the bluish discoloration that can appear when heavier fillers are placed too superficially) makes it useful for very fine perioral lines and superficial corrections where other products would look unnatural.
Who Is a Good Candidate?
Most adults in good general health who notice volume loss, deepened folds, or changes in lip definition are candidates for dermal fillers. The clearest signs: cheeks that look flatter or more shadowed than they used to; nasolabial folds that are visible at rest (not just when smiling); lip volume or definition that has thinned; under-eye hollows that make you look tired regardless of how well you’ve slept; or a jawline that has become less defined.
Contraindications include pregnancy and breastfeeding, active skin infection at the intended treatment site, allergy to filler components (rare), and certain autoimmune or clotting disorders that require physician clearance. Patients on significant anticoagulation therapy should discuss timing with their prescribing physician. The $100 consultation at Capital Skin is the right place to work through these questions — Dr. Purcell will review your medical history and tell you clearly whether fillers are appropriate, and if so, which approach makes the most sense.
Dr. Purcell on the natural-results standard:
“The patients I see who are most unhappy with prior filler work — at other practices — weren’t over-treated in one session. They were under-counseled about what conservative staging looks like, and they ended up adding volume on top of volume. My approach is always less than you think you need at first. We look at results at two weeks, when everything has settled, and decide together whether a refinement makes sense. That’s how you get results that last without looking like you had anything done.”
External authorities: FDA Dermal Fillers guidance · JUVÉDERM manufacturer site · Restylane manufacturer site · Radiesse manufacturer site · NIH review — tear trough anatomy and treatment
